Baum Jason

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · derivative · entry 3

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · nonDerivative · entry 2

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,896

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · nonDerivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-24-106330 · tm2425653-1_4seq1.xml · derivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-009027 · tm244775-6_4seq1.xml · derivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-23-095368 · tm2324823-14_4seq1.xml · derivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2033-08-23

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on September 23, 2023 and an additional of such monthly installments vesting on the 23rd day of each calendar month thereafter.